Evidence map›Paper›PMID 35032963›Full record

ArticleALTEX2022

COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.

Laure-Alix Clerbaux, Núria Amigó, Maria João Amorim, Anna Bal-Price, Sofia Batista Leite, Anna Beronius, Gillina F G Bezemer, Ann-Charlotte Bostroem, Annamaria Carusi, Sandra Coecke and 48 more

Abstract readEditorial
In one paragraph

Article in ALTEX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

58 authors.

Laure-Alix ClerbauxEuropean Commission, Joint Research Centre, Ispra, Italy.
Núria AmigóBiosfer Teslab, Reus, Spain.
Maria João AmorimInstituto Gulbenkian de Ciência, Lisbon, Portugal.
Anna Bal-PriceEuropean Commission, Joint Research Centre, Ispra, Italy.
Sofia Batista LeiteEuropean Commission, Joint Research Centre, Ispra, Italy.
Anna BeroniusInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Gillina F G BezemerImpact Station, Hilversum, The Netherlands.
Ann-Charlotte BostroemEuropean Commission, Joint Research Centre, Ispra, Italy.
Annamaria CarusiInterchange Research, London, UK.
Sandra CoeckeEuropean Commission, Joint Research Centre, Ispra, Italy.
Rachel ConchaFairleigh Dickinson University, Green Neuroscience Laboratory, San Diego, CA, USA
Evangelos P DaskalopoulosEuropean Commission, Joint Research Centre, Ispra, Italy.
Francesca De BernardiDivision of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Eizleayne EdrosaGreen Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
Steve W EdwardsRTI International, Research Triangle Park, NC, USA.
Julija FilipovskaIndependent scientist, Ohrid, North Macedonia.
Natàlia Garcia-ReyeroUS Army Engineer Research and Development Center, Vicksburg, MS, USA.
Felicity N E GavinsThe Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK.
Sabina HalappanavarEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
Alan J HargreavesSchool of Science and Technology, Nottingham Trent University, Nottingham, UK.
Helena T HogbergJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mylène T HuynhDepartment of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Daniel JacobsonBiosciences, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
Jonathan Josephs-SpauldingInstitute for Experimental Medicine, Kiel University, Kiel, Germany.
Young Jun KimKorea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
Hyun Joon KongUniversity of Illinois at Urbana-Champaign, Champaign, IL, USA.
Catharine E KrebsPhysicians Committee for Responsible Medicine, Washington, DC, USA.
Ann LamGreen Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
Brigitte LandesmannEuropean Commission, Joint Research Centre, Ispra, Italy.
Adrienne LaytonUS Consumer Product Safety Commission, Bethesda, MD, USA.
Yong Oh LeeKorea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany.
Donna S MacmillanHumane Society International, Washington, DC, USA.
Alberto MantovaniIstituto Superiore di Sanità, Rome, Italy.
Luigi Margiotta-CasaluciThe Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK.
Marvin MartensDepartment of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands.
Rosalinde MasereeuwUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Sally A MayasichUniversity of Wisconsin-Madison Aquatic Sciences Center at US EPA, Duluth, MN, USA.
Liang Merlin MeiUS EPA, Durham, NC, USA.
Holly MortensenUS EPA, Durham, NC, USA.
Amalia Munoz PineiroEuropean Commission, Joint Research Centre, Geel, Belgium.
Penny NymarkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Elan OhayonGreen Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
Joshi OjasiHiranandani College of Pharmacy, Mumbai, India.
Alicia PainiEuropean Commission, Joint Research Centre, Ispra, Italy.
Nikolaos ParissisEuropean Commission, Joint Research Centre, Ispra, Italy.
Surat ParvatamCentre for Predictive Human Model Systems Atal Incubation Centre - Centre for Cellular and Molecular Biology Habsiguda, Hyderabad, India.
Francesca PistollatoEuropean Commission, Joint Research Centre, Ispra, Italy. Francesca.PISTOLLATO@ec.europa.eu.
Magdalini SachanaEnvironment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), Paris, France.
Jorid Birkelund SørliThe National Research Centre for the Working Environment, Copenhagen, Denmark.
Kristie M SullivanPhysicians Committee for Responsible Medicine, Washington, DC, USA.
Jukka SundEuropean Commission, Joint Research Centre, Ispra, Italy.
Shihori TanabeDivision of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki, Japan.
Katya TsaiounJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mathieu VinkenDepartment of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
Laura VivianiHumane Society International, Washington, DC, USA.
Jennifer WaspeSheffield Teaching Hospitals, Sheffield, UK.
Catherine WillettHumane Society International, Washington, DC, USA.
Clemens WittwehrEuropean Commission, Joint Research Centre, Ispra, Italy.

Funding

Research Initiatives on COVID-19 in the Division of Translational ToxicologyZIAES103367 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GERMOLEC, DORI R · 2021 to 2025
$4.5M
USING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0M
Intramural EPA EPA999999NIA NIH HHS RF1 AG053303
6 · The paper itself

Abstract

On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and posi­tioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowd­sourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, inte­grating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.

Indexed as

Adverse Outcome PathwaysCOVID-19HumansPost-Acute COVID-19 SyndromeSARS-CoV-2adverse outcome pathwayCOVID-19interdisciplinarity

Identifiers

PMID35032963
PMCPMC10069302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.